Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat with Gem/Clo/Bu Conditioning for Aggressive Lymphoma
NCT04220008Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2021
- Primary completion
- Oct 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
01
Overview
Phase 2, open-label trial of vorinostat in non-Hodgkin lymphoma (NHL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression-free survival at 3 years. Planned start Oct 2021; status: withdrawn.
02
Drugs
vorinostat
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04220008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04220008.